NICE ‘fast-tracking’ underlines threat from BMS/Pfizer’s Eliquis to Pradaxa and Xarelto
This article was originally published in Scrip
The positive reimbursement decision from NICE on 23 January means that Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) means will likely start competing with Boehringer Ingelheim's Pradaxa (dabigatran etexilate) and Bayer's Xarelto (rivaroxaban) in stroke prevention as early as next month, February 2013. Datamonitor analyst Victoria Hudson, says Eliquis will compete well against its rival novel anticoagulants even in a market where uptake of warfarin-replacements has been slower than expected.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.